Investview Reports Significant Revenue Decline and Net Loss in Q3 2025

Investview, Inc. reported a significant decline in financial performance for the third quarter and the first nine months of 2025, as detailed in its latest 10-Q filing. For the three months ended September 30, 2025, the company generated total revenue of $9.05 million, a decrease of 23% from $11.74 million in the same period of 2024. The decline was primarily driven by a 37% drop in membership revenue, which fell to $7.07 million from $11.18 million, attributed to a global economic downturn affecting consumer spending. However, the company saw increases in mining revenue, which rose to $923,603 from $567,415, and health and wellness product sales, which contributed $1.03 million following the acquisition of Renu Laboratories in October 2024.

In terms of profitability, Investview reported a net loss of $852,363 for the third quarter of 2025, compared to a loss of $810,648 in the prior year. The nine-month results were similarly affected, with total revenue declining to $29.11 million from $40.52 million, marking a 28% decrease. The net loss for the nine months ended September 30, 2025, was $1.11 million, a stark contrast to a net income of $1.39 million for the same period in 2024. The company attributed these losses to reduced membership and mining revenues, alongside increased operational costs.

Operationally, Investview has made strategic moves, including the acquisition of Renu Laboratories, which has expanded its health and wellness product offerings. The company reported a total of 1,859,231,786 shares of common stock issued as of September 30, 2025, with a treasury stock of 8,501,503 shares. The company’s cash and cash equivalents stood at $15.08 million, down from $22.47 million at the end of 2024, reflecting a decrease in liquidity. The total liabilities decreased to $10.84 million from $14.37 million, indicating improved financial management.

Looking ahead, Investview's management expressed confidence in its ability to meet short- and long-term obligations, citing sufficient cash reserves and a strategic focus on expanding its digital asset holdings and health product sales. The company has also adopted new accounting standards for digital assets, which will impact future financial reporting. Despite the current challenges, management believes that the ongoing adjustments and acquisitions will position the company for recovery and growth in the coming quarters.